NasdaqCM - Nasdaq Real Time Price USD

Applied DNA Sciences, Inc. (APDN)

4.3700 -0.6300 (-12.60%)
At close: April 26 at 4:00 PM EDT
4.3300 -0.04 (-0.92%)
After hours: April 26 at 6:45 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Total Revenue
8,995.8550
13,367.4430
18,168.6770
9,027.7380
1,931.4970
Cost of Revenue
5,609.0090
7,834.0110
13,115.0370
4,544.8320
827.8230
Gross Profit
3,386.8460
5,533.4320
5,053.6400
4,482.9060
1,103.6740
Operating Expense
16,910.2240
16,486.7220
19,023.4030
17,009.8060
13,638.6730
Operating Income
-13,523.3780
-10,953.2900
-13,969.7630
-12,526.9000
-12,534.9990
Net Non Operating Interest Income Expense
104.9690
75.3320
7.2000
13.6750
-115.8300
Other Income Expense
6,109.4580
855.0420
5,692.5040
-1,765.2140
-378.0750
Pretax Income
-7,308.9510
-10,022.9160
-8,270.0590
-14,278.4390
-13,028.9040
Net Income Common Stockholders
-7,286.5440
-9,947.0590
-8,377.9960
-14,286.4420
-13,030.0610
Diluted NI Available to Com Stockholders
-7,286.5440
-9,947.0590
-8,377.9960
-14,286.4420
-13,030.0610
Basic EPS
-0.55
-0.76
-0.93
-2.07
-3.32
Diluted EPS
-0.55
-0.76
-0.93
-2.07
-3.32
Basic Average Shares
13,266.6440
13,075.4160
8,967.7040
6,916.9990
3,919.0720
Diluted Average Shares
13,266.6440
13,075.4160
8,967.7040
6,916.9990
3,919.0720
Total Operating Income as Reported
-13,523.3780
-10,953.2900
-13,969.7630
-13,348.6410
-12,534.9990
Total Expenses
22,519.2330
24,320.7330
32,138.4400
21,554.6380
14,466.4960
Net Income from Continuing & Discontinued Operation
-7,208.7870
-9,947.0590
-8,267.8910
-14,286.4420
-13,027.2190
Normalized Income
-13,339.9870
-10,801.4590
-14,007.7000
-12,529.9840
-13,027.2190
Interest Income
104.9690
75.3320
7.2000
13.6750
--
Interest Expense
--
--
--
--
115.8300
Net Interest Income
104.9690
75.3320
7.2000
13.6750
-115.8300
EBIT
-13,523.3780
-10,953.2900
-13,969.7630
-12,526.9000
-12,534.9990
EBITDA
-12,201.0960
-9,591.0410
-12,679.2830
-11,682.4620
-12,249.2690
Reconciled Cost of Revenue
5,609.0090
7,834.0110
13,115.0370
4,544.8320
827.8230
Reconciled Depreciation
1,322.2820
1,362.2490
1,290.4800
844.4380
285.7300
Net Income from Continuing Operation Net Minority Interest
-7,208.7870
-9,947.0590
-8,267.8910
-14,286.4420
-13,027.2190
Total Unusual Items Excluding Goodwill
6,131.2000
854.4000
5,739.8090
-1,756.4580
--
Total Unusual Items
6,131.2000
854.4000
5,739.8090
-1,756.4580
--
Normalized EBITDA
-18,332.2960
-10,445.4410
-18,419.0920
-9,926.0040
-12,249.2690
9/30/2020 - 7/15/2003

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TTOO T2 Biosystems, Inc.
2.8400
+3.65%
 
ISPC iSpecimen Inc.
0.2660
-5.07%
 
MYNZ Mainz Biomed N.V.
0.8181
-4.52%
 
PRE Prenetics Global Limited
4.6100
-7.24%
 
DMTK DermTech, Inc.
0.6031
+3.02%
 
BIAF bioAffinity Technologies, Inc.
2.3700
-1.66%
 
BNR Burning Rock Biotech Limited
0.8500
0.00%
 
VNRX VolitionRx Limited
0.9137
+2.65%
 
TWST Twist Bioscience Corporation
31.54
+1.48%
 
CHEK Check-Cap Ltd.
2.2850
-0.65%